IQVIA Biotech won a competitive bid for a pair of global Phase III prostate cancer trials from a small biopharmaceutical company. Eighteen months into the study the sponsor was acquired by a leading global pharmaceutical company. The acquisition greatly accelerated the trial timeline and created different points of emphasis for the study team which needed to be operationalized while continuing to aggressively move the study forward. In addition, patient and investigator excitement about the compound drove accrual much faster than anticipated, which created a hurdle not common to oncology trials